Quarry LP’s Keros Therapeutics KROS Stock Holding History

Quarry LP’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,417	Closed	-$22.4K	–	2393
2025 Q3	$22.4K	Buy	+1,417	New	+$20.9K	﹤0.01%	1332

Other funds holding KROS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Quarry LP's KROS Position: Q4 2025 in Review

Quarry LP sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 1,417 shares — an estimated $22.4K sold.

Quarry LP first reported a position in KROS in Q3 2025 and held it in 1 quarter. The position peaked at $22.4K in Q3 2025. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

Quarry LP reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
Quarry LP sold 1,417 Keros Therapeutics shares in Q4 2025, an estimated $22.4K.
Quarry LP first reported a position in Keros Therapeutics in Q3 2025 and held it in 1 quarter.
Quarry LP's Keros Therapeutics position peaked at $22.4K in Q3 2025.
166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on Quarry LP's 13F filing for Q4 2025, filed 13 Feb 2026.